Humana (NYSE:HUM) Downgraded by StockNews.com to Hold

Humana (NYSE:HUM) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

Several other analysts have also issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Truist Financial lifted their target price on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Barclays lifted their target price on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. Finally, Piper Sandler lifted their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $285.68.

Humana Stock Up 4.5 %

HUM stock opened at $264.39 on Tuesday. The firm has a market cap of $31.91 billion, a PE ratio of 26.57, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The firm’s fifty day moving average is $271.39 and its 200 day moving average is $278.89. Humana has a one year low of $213.31 and a one year high of $406.46.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, research analysts forecast that Humana will post 16.47 EPS for the current year.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is owned by insiders.

Institutional Investors Weigh In On Humana

A number of institutional investors and hedge funds have recently made changes to their positions in HUM. Mutual of America Capital Management LLC raised its stake in shares of Humana by 12.4% in the 3rd quarter. Mutual of America Capital Management LLC now owns 21,717 shares of the insurance provider’s stock valued at $6,879,000 after acquiring an additional 2,395 shares during the period. Quest Partners LLC purchased a new stake in shares of Humana in the 3rd quarter valued at approximately $701,000. Banque Cantonale Vaudoise raised its stake in shares of Humana by 8.9% in the 3rd quarter. Banque Cantonale Vaudoise now owns 11,387 shares of the insurance provider’s stock valued at $3,606,000 after acquiring an additional 927 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Humana in the 3rd quarter valued at approximately $1,778,000. Finally, Jennison Associates LLC raised its stake in shares of Humana by 4.4% in the 3rd quarter. Jennison Associates LLC now owns 333,725 shares of the insurance provider’s stock valued at $105,704,000 after acquiring an additional 13,945 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.